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Apolipoprotein M (apoM) is the carrier of
sphingosine-1-phosphate (S1P) in
lipoproteins. Christoffersen et al. show
that lack of apoM in mice increases the
amount of brown adipose tissue,
accelerates the turnover of fat, and
protects against obesity. The results
reveal a link between the apoM/S1P axis
and energy metabolism.
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Apolipoprotein M (apoM) is the carrier of sphingo-
sine-1-phosphate (S1P) in plasma high-density lipo-
proteins. S1P is a bioactive lipid interacting with five
receptors (S1P1–5). We show that lack of apoM in
mice increases the amount of brown adipose tissue
(BAT), accelerates the clearance of postprandial tri-
glycerides, andprotectsagainstdiet-inducedobesity
(i.e., a phenotype similar to that induced by cold
exposure or b3-adrenergic stimulation). Moreover,
the data suggest that the phenotype of apoM-defi-
cient mice is S1P dependent and reflects diminished
S1P1 stimulation. The results reveal a link between
the apoM/S1P axis and energy metabolism.INTRODUCTION
Excessive caloric intake and insufficient energy expenditure
leads to storage of triglycerides in adipose tissues and obesity.
Obesity is the prominent cause of insulin resistance and type 2
diabetes in affluent societies (Horton, 1983). Hence, a detailed
understanding of processes controlling triglyceride metabolism
is warranted to identify new measures to prevent obesity. White
adipose tissue (WAT) stores nonutilized energy as triacylglycer-
ols, which can be released as nonesterified fatty acids for energy
consumption inmetabolically active organs under catabolic con-
ditions. Brown adipose tissue (BAT), characterized by expres-
sion of the uncoupling protein 1 (UCP1), uses fatty acids released
from intracellular triglyceride stores for b-oxidation to generate
heat by a process known as adaptive thermogenesis (Cannon
and Nedergaard, 2004).
Short-term cold exposure increases the activity of BAT and
improves insulin sensitivity in patients with type 2 diabetes
(Hanssen et al., 2015). BAT also can be activated by the stimula-
tion of the b3-adrenergic receptors (AdrB3) (Lowell and Flier,Ce
This is an open access article under the CC BY-N1997). Both cold exposure and treatment with a b3 agonist
(e.g., CL316243) reduce body weight and alleviate diabetes as
well as atherosclerosis in rodents (Bartelt et al., 2011; Berbe´e
et al., 2015; Cawthorne et al., 1984; Peirce and Vidal-Puig,
2013; Vallerand et al., 1986). These beneficial effects occur in
parallel with increased uptake and metabolism of glucose in
BAT. Moreover, activated BAT clears triglyceride-rich lipopro-
teins from the blood (Bartelt et al., 2011). Triglyceride-rich lipo-
proteins interact with CD36 and lipoprotein lipase (LPL) on the
surface of endothelial cells in BAT (Bartelt et al., 2011). As
such, both whole-particle uptake by brown adipocytes and of
hydrolyzed triglycerides as free fatty acids (FFAs) are possible
pathways for metabolizing triglyceride-rich lipoproteins in BAT
(Bartelt et al., 2011; Khedoe et al., 2015).
Sphingosine-1-phosphate (S1P) is a bioactive lipid interacting
with 5 different receptors (S1P1–5), mediating effects such as
angiogenesis, migration of lymphocytes, and induction of tight
junctions between endothelial cells (Camerer et al., 2009; Garcia
et al., 2001; Lee et al., 1999; Pappu et al., 2007). S1P1 is the best
characterized receptor. It plays an important role in maintaining
the endothelial barrier (Camerer et al., 2009; Garcia et al., 2001;
Liu et al., 2000; Nofer et al., 2004; Paik et al., 2001). The endothe-
lial barrier is compromised in diseases such as multiple sclerosis
characterized by migration of lymphocytes across the blood-
brain barrier (Grigoriadis et al., 2015; Prager et al., 2015).
Patients with multiple sclerosis benefit from treatment with
the S1P analog fingolimod (Kim et al., 2015). Fingolimod also
reduces the inflammatory response after transplantation-associ-
ated reperfused ischemia in lung tissue and in damaged pancre-
atic b cells of diabetic animal models (Moon et al., 2013; Penar-
anda et al., 2010; Stone et al., 2015).
High-density lipoproteins (HDLs) protect endothelial cells.
HDLs carry more than 40 different apolipoproteins, including
apolipoproteinM (apoM) (Davidson et al., 2009). ApoM is amem-
ber of the lipocalin superfamily (Christoffersen et al., 2011; Duan
et al., 2001) and contains a binding pocket for small lipophilic
molecules. As such, apoM is the carrier of Sphingosine-1-phos-
phate (S1P) in plasma lipoproteins (Christoffersen et al., 2011).ll Reports 22, 175–188, January 2, 2018 ª 2017 The Author(s). 175
C-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
Approximately 65%of plasmaS1P is bound to apoM inHDLsand
30% isbound to albumin (Karuna et al., 2011;Murata et al., 2000).
ApoM-deficient mice with a lack of HDL-associated S1P display
increased vascular permeability in the lungs, suggesting that the
apoM/S1P axis is needed to maintain normal vascular barrier
function (Christensen et al., 2016; Christoffersen et al., 2011).
Herein, we present data suggesting that an apolipoprotein,
apoM, controls BAT activity and that this effect is mediated
by an associated sphingolipid, S1P. Also, we show that the
apoM/S1P axis has major effects on postprandial triglyceride
metabolism and diet-induced obesity. The findings have poten-
tial therapeutic implications since we also find that stimulation
of S1P1 by, e.g., FTY720, mimics the beneficial effects of
apoM deficiency. Together, the results reveal a link between
the apoM/S1P axis and energy metabolism.
RESULTS
Decreased WAT and Increased BAT in ApoM-Deficient
Mice
Apom/ mice have reduced body weight (Figure S1A). To
explore this finding, we assessed the lean and adipose tissue
masses of female mice housed at 23C. On MRI, the fat mass
(Figure 1A), but not the lean mass (Figure S1B), was lower in
Apom/ than in wild-type mice. Upon postmortem dissection,
the weight of the intra-abdominal epididymal WAT (epiWAT)
was reduced by 60% (Figure 1B), whereas the weight of both
interscapular (IsBAT) and subscapular (SubBAT) BAT (Figure 1C)
was increased in Apom/ compared to wild-type mice. On
positron emission tomography-computed tomography (PET-CT)
scanning using 18F-flurodeoxyglucose (FDG), the FDG uptake by
BAT tended to be higher in Apom/mice than in wild-type mice
(Figures 1D and 1E). These findings suggest that apoM defi-
ciency results in decreased deposition of fat in WAT, possibly
as a result of increased BAT activity.
Next, we compared structural and biochemical characteristics of
BAT in Apom/ mice and wild-type mice housed at 23C. BAT is
characterized by a high content of the mitochondria-membrane
lipid cardiolipin and of the uncoupling protein 1 (UCP1) (Faber
et al., 2014; Golozoubova et al., 2001; Lee et al., 2015). Both cardi-
olipin (Figure 2A) andUCP1 (Figure 2B; Figure S2)weremore abun-
dant in BAT from Apom/mice than from wild-type mice. On his-
tological examination, Apom/ mice had more but smaller lipid
droplets in BAT than did wild-type mice (Figures 2C–E). Also, the
mRNA expression of the glucose transporter GLUT4 and AdrB3
was increased, whereas mRNA expression of peroxisome prolifer-
ator-activated receptor gamma coactivator 1-a (PGC-1a), a tran-
scriptional co-regulator of various genes involved in energy meta-
bolism) was decreased in BAT from Apom/ mice as compared
to wild-type mice (Figure 2F). Combined, these data suggest that
apoM deficiency increases the metabolic activity of BAT. Notably,
in WAT, the expression of LPL, CD36, and GLUT4 mRNA were
increased inApom/micecompared towild-typemice (Figure2F).
Abrogated Response of BAT to Cold Exposure or
b3-Adrenergic Stimulation in Apom
/ mice
BAT activity in wild-type mice can be increased by cold expo-
sure (Cannon and Nedergaard, 2004; Lowell and Flier, 1997).176 Cell Reports 22, 175–188, January 2, 2018Accordingly, in wild-type mice kept at 4C for 6 days, the weight
of BAT was increased and that of WAT was decreased (Fig-
ure 3A) compared to wild-type mice kept at 23C (Figures 1B
and 1C). In contrast, in Apom/ mice, BAT and WAT weights
were not affected by cold exposure. Hence, Apom/ and
wild-type mice had similar BAT and WAT weights when housed
at 4C (Figure 3A). Also, at 4C, the number (Figure 3B) and size
(Figure 3C) of lipid droplets, as well as the contents of UCP1 pro-
tein (Figure 3D and S2) and cardiolipin (Figure 3E) in BAT, were
similar in Apom/and wild-type mice. Moreover, the effects of
apoM deficiency on BAT and WAT mRNA expression were
markedly dampened or abrogated in mice kept at 4C (Fig-
ure 3F). To explore whether the acute response to cold also
was abrogated, BAT weight was measured in Apom/ and
wild-type mice that had been kept at 4C for 16 hr. Under these
conditions wild-type mice had an increased mass of BAT
compared to mice kept at 23C, but the difference was less pro-
nounced than after 6 days of housing (Figures 1C, 3A, and 3G).
After 16 hr at 4C, Apom/ mice had less BAT mass than wild-
type mice and similar BAT mass compared to Apom/ mice
housed at 23C or 4C for 6 days (Figures 1C, 3A, and 3G).
Like cold exposure, treatment with the adrenergic b3-receptor
agonist CL316243 (Lowell and Flier, 1997) increased BAT and
decreased WAT weights in wild-type mice housed at 23C (Fig-
ure 3H). CL316243 also increased BAT volume as assessed with
PET-CT (Figure 1E). As for cold exposure, these effects of
CL316243 were absent in Apom/ mice (Figures 1E and 3H).
Increased Uptake of Triglycerides in BAT of Apom/
Mice
Upon cold exposure or nergic b3-receptor stimulation, activated
BAT becomes a major tissue site for the clearance of plasma
triglycerides from the circulation (Bartelt et al., 2011). We as-
sessed whether the increased BAT in Apom/ mice kept at
23C likewise accelerates triglyceride metabolism. Remarkably,
upon intragastric administration of a bolus of olive oil, the pro-
nounced increase of the plasma triglyceride concentration seen
inwild-typemicewasalmost absent inApom/mice (Figure 4A).
Also, fasting plasma triglyceride concentrations were 30%
lower in Apom/ mice than in wild-type mice (Christoffersen
et al., 2008). LPL plays a key role in peripheral removal of plasma
triglycerides by lipolysis (Williams and Fisher, 2011). The plasma
LPL activity after the injection of heparin was increased in
Apom/ mice compared to wild-type mice (Figure 4B). More-
over, when lipolysis was blocked with Triton WR-1339, the
plasma triglyceride concentration increased at the same rate in
fasting Apom/ mice and wild-type mice (Figure 4C). Hence,
the reduced plasma triglyceride concentrations in Apom/
mice likely reflect increased peripheral clearance involving LPL.
To examine the metabolic fate of the postprandial plasma
triglycerides, olive oil was administered intragastrically together
with 3H-triolein. 3H-triolein uptake wasmarkedly increased in the
IsBAT of Apom/ mice compared with wild-type mice (Fig-
ure 4D). Also, double-labeled 3H-cholesterylhexadecylether
and 14C-triolein chylomicron-like particles were injected intrave-
nously to assess whole-particle uptake by tissues (Figures 4E
and 4F). The uptake of the double-labeled particles was
increased both in BAT and WAT of Apom/ mice compared
Figure 1. Apolipoprotein M Affects the Mass of WAT and BAT at 23C
(A) Mass of fat analyzed by EchoMRI scanning of Apom/ (n = 7) and wild-type mice (n = 6).
(B and C) Mass of epiWAT (B) and BAT, including IsBAT and SubBAT (C) in wild-type (n = 6) mice and Apom/ (n = 7) mice.
(D) Representative PET-CT images from animals housed at 23C. White and red arrows indicate FDG uptake in BAT and heart, respectively.
(E) BAT volume measured by PET-CT scanning in mice (n = 4) receiving either saline or b3 agonist CL316243 subcutaneously before FDG.
Error bars represent SEM. #p < 0.05 analyzed by Student t test. See also Figure S1.to wild-typemice. Interestingly, theApom/mice in parallel dis-
played a reduced uptake of the double-labeled whole lipoprotein
particles in the heart, possibly reflecting a shift in energy utiliza-
tion. These data reveal that apoM deficiency increases the up-
take of plasma triglycerides in BAT.Protection against Diet-Induced Obesity in Apom/
Mice
Activated BAT protects against diet-induced obesity (Cawthorne
et al., 1984; Peirce and Vidal-Puig, 2013; Vallerand et al.,
1986). We, therefore, hypothesized that Apom/ mice wouldCell Reports 22, 175–188, January 2, 2018 177
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be resistant to obesity when fed a high-fat diet. Indeed, feeding
a diet containing 60% fat for 10 weeks resulted in lower body
weight (28.4 ± 1.2 g versus 33.9 ± 1.1 g, p < 0.01) in Apom/
mice than in wild-type mice (Figure S3A). Accordingly, glucose
tolerance tests were improved in Apom/ mice compared to
wild-typemice after 10weeks of being fed a high-fat diet (Figures
4G and 4H).
To examine the effect of apoM on energy utilization, lean
mice were placed in metabolic cages. At 23C there were no
differences between Apom/ mice and wild-type mice in
food or water intake or energy consumption. Increased energy
consumption was observed upon refeeding after 24 hr of fast-
ing at 23C. Here, the respiratory exchange rate (RER) was
reduced in Apom/ mice, indicating a higher utilization of
fat (compared to carbohydrate) than that in wild-type mice
(Table 1), which may be a result of the slightly lower food
intake observed in these mice. At 23C the animals also
were fed a high-fat diet after 12 hr of fasting (Table S1). On a
high-fat diet, the Apom/ mice had reduced food intake and
a tendency toward reduced calorie consumption compared
to wild-type mice. The RER levels were similar in Apom/
mice and wild-type mice.
Spuriously, the core body temperature of the Apom/ mice
was slightly lower than in the wild-type mice at 4C, 23C, and
30C (Table 1). The latter finding could reflect increased heat
loss, either via the tail or from the body surface, because the tem-
perature was higher in Apom/ mice than in wild-type mice
when recorded with an infrared camera (Figures S3B–S3E).
To test the effect of acute cold on body temperature andmeta-
bolic activity, animals were examined during 16 hr of acute expo-
sure to 4C. The core body temperature significantly dropped in
Apom/ mice compared to wild-type mice (Figure S4). Like-
wise, after 12 hr of exposure to 4C, the RER was reduced in
Apom/ mice compared to wild-type mice without any signifi-
cant change in food intake, water intake, or activity.
BAT Activation Mediated by Decreased S1P1 Receptor
Stimulation
Because apoM is the physiological carrier of S1P (Christof-
fersen et al., 2011), the effects of apoM deficiency on BAT
could be mediated by altered stimulation of S1P receptors.
Therefore, the cellular distribution of S1P1 and S1P3–5 receptor
mRNA in BAT and WAT was analyzed after fluorescence-
activated cell (FACS) sorting of endothelial cells (CD31+ cells),
macrophages (CD11+ cells), and adipocytes (flow-through)
(Figure S5). S1P1 mRNA was expressed mainly in the endothe-
lial cells (Figure S5A), whereas S1P3 mRNA was seen mainly in
the adipocytes (Figure S5B). S1P4 and S1P5 receptor mRNAFigure 2. Apolipoprotein M Affects BAT Morphology and mRNA Expre
(A) Cardiolipin expressed per milligram tissue wet weight of BAT from wild-type
(B) UCP1 in protein extracts from BAT in Apom/ (n = 5) mice and wild-type m
standard curve using 5, 10, 30, 50, and 70 mg total proteins.
(C) HE-stained sections of BAT.
(D and E) Numbers (D) and diameter (E) of lipid droplets in BAT from HE-stained
(F) mRNA expression in Apom/ mice (n = 8) calculated as percentage of the m
FATP1, fatty acid transporter protein 1; DIO2, deiodinase iodothyronine type 2; C
t test. See also Figure S2.expressions were below the detection limit of the RT-PCR
assays.
FTY720 (i.e., Fingolimod) is anS1Panalog used in the treatment
of patients with multiple sclerosis (Kim et al., 2015). In mice,
FTY720 (0.5 mg/kg) works as a functional S1P1 receptor antago-
nist, but it also can interact with S1P3–5 (Brinkmann et al., 2002;
Mandala et al., 2002). When administered to wild-type mice,
FTY720 (0.5 mg/kg) increased IsBAT weight (Figure 5A). This ef-
fect was absent in the Apom/mice, implying that the increased
weight of BAT in apoM deficiency is S1P dependent.
To further address the putative involvement of S1P1 receptors
in BAT formation, wild-type mice and Apom/ mice were
treated with an S1P1 receptor antagonist (W146) or an S1P1 re-
ceptor agonist (SEW2871). In wild-type mice, S1P1 receptor
antagonismwithW146 increased BATweight, whereas S1P1 ag-
onism with SEW2871 had no effect on BAT weight. In Apom/
mice, S1P1 receptor agonism with SEW2871 decreased BAT
weight, and S1P1 receptor antagonism with W146 had no effect
(Figure 5B). BAT weight was not affected when Apom/ mice
and wild-type mice were treated with either an S1P3 receptor
antagonist (Bml-241) or an agonist (Cym-5541) (data not shown).
Together, these results imply that inhibition of the S1P1 receptor
increases BAT formation.
To explore whether diminished stimulation of the S1P1
receptor per se could induce browning of adipocytes, pre-ad-
ipocytes were differentiated into beige adipocytes in the pres-
ence of HDL-apoM, HDL+apoM, S1P, SEW2871, FTY720,
or W146. The UCP1 mRNA expression increased when cells
were exposed to HDL-apoM, FTY720, or W146. In contrast
HDL+apoM, SEW2871, and S1P tended to reduce UCP1
mRNA expression (Figure 5C). The in vivo biology is, however,
more complex, as to why analysis of cultured adipocytes
may not be sufficient to mimic an interplay between surround-
ing cell types such as endothelial cells expressing S1P1 and
adipocytes.
S1P1 receptor mRNA was confined mainly to endothelial cells
(Figure S5A). The S1P1 receptors are central to controlling
endothelial permeability in the lungs (Christensen et al., 2016).
Therefore, we examined the effect of FTY720 and apoM on the
BAT endothelial permeability, as judged by the uptake of Evans
Blue after intravenous injection. The Apom/ mice had mark-
edly increased Evans Blue uptake in BAT as compared to the
wild-type mice. In the wild-type mice, administration of FTY720
increased Evans Blue uptake in BAT (Figure 5D) and completely
eliminated the difference in BAT Evans Blue uptake between
wild-type mice and Apom/ mice (Figure 5D). Hence, the data
suggest that apoM preserves the endothelial permeability of
BAT in an S1P1 receptor-dependent manner.ssion in Mice Housed at 23C
(n = 7) mice and Apom/ (n = 8) mice.
ice (n = 4). UCP1 levels were normalized with GAPDH and analyzed against a
sections from 4 Apom/ and wild-type mice.
ean expression in wild-type mice (n = 7).
yCs, cytochrome c. Error bars represent SEM. #p < 0.05 analyzed by Student’s
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Increased Triglyceride Metabolism in Apom/ Mice Is
S1P Dependent
Because the infrared recordings suggested that the Apom/
mice lose heat from the tail at 23C (Figures S3B and S3C),
it was conceivable the increased BAT formation in Apom/
mice could be affected by the, albeit rather modest, reduction
of core body temperature. We, therefore, housed mice at
30C. At this temperature, the heat loss from the tail was similar
in Apom/ mice and wild-type mice (Figure S6). In accordance
with previous studies of mice kept at 28C–30C (Wu et al.,
2011), BAT uptake of FDG was not detectable on PET-CT either
in Apom/ mice or in wild-type mice, unless stimulated with
CL316243 (Figure 5E). Nevertheless, upon intragastric adminis-
tration of a bolus of olive oil, the plasma triglyceride concentra-
tion still increased less in Apom/ mice than in wild-type mice
(Figure 5F), suggesting that the effect of apoM deficiency on
plasma triglyceride catabolism is not secondary to heat loss-
induced BAT formation. FTY720-treated mice were furthermore
subjected to an intragastric bolus of olive oil and 3H-triolein.
In wild-type mice, FTY720 diminished the olive oil-induced in-
crease of plasma triglycerides (Figure 5G) and increased the up-
take of 3H-triolein in BAT (Figure 5H). These effects of FTY720
were not present in Apom/ mice. This further supports the
notion that the effect of apoM deficiency on plasma triglyceride
removal in BAT is mediated directly via the S1P system.
DISCUSSION
The present results demonstrate a link between the apoM/S1P
axis, BAT, and triglyceride metabolism. We show that the lack
of apoM in mice increases the amount of BAT, accelerates the
clearance of postprandial triglycerides, protects against diet-
induced obesity, and improves glucose tolerance, i.e., a pheno-
type similar to that induced by cold exposure or b3-adrenergic
stimulation (Bartelt et al., 2011). Moreover, the data suggest
that the phenotype of apoM-deficient mice is S1P dependent
and reflect diminished S1P1 receptor stimulation.
The results imply that the apoM/S1P axis directly affects endo-
thelial function in BAT in an S1P1-dependent manner because
S1P1 receptor mRNA was robustly expressed in the BAT endo-
thelial cell fraction and because the Apom/ mice displayed
increased BAT endothelial permeability. Also, FTY720-treated
wild-type mice had increased BAT endothelial permeability and
turnover of triglycerides compared to untreated wild-type mice.Figure 3. Deficiency of Apolipoprotein M Abrogates the Effects of b3-A
(A) Adipose tissue mass in Apom/ (n = 8) mice or wild-type (n = 8) mice after c
(B and C) Quantification of diameter (C) or numbers (B) of lipid droplets in BAT f
exposure (4C) for 6 days.
(D) UCP1 in protein extracts from BAT in Apom/ (n = 5) mice and wild-type (n =
GAPDH.
(E) Cardiolipin expressed per milligram tissue wet weight of BAT from wild-type
(F) mRNA expression in Apom/ (n = 8) mice calculated as percentage of the m
FATP1, fatty acid transporter protein 1; DIO2, deiodinase iodothyronine type 2; C
(G) Adipose tissue mass in Apom/ (n = 8) mice or wild-type (n = 8) mice after 1
(H) Adipose tissuemass inwild-typemice andApom/mice after treatment subc
genotype). Mice were housed at 23C.
Error bars represent SEM. *p < 0.05 using one-way ANOVAwith Bonferroni post h
Figure S2.Increased vascular permeability after FTY720 stimulation in
wild-type mice also has been observed in lung tissue (Oo et al.,
2011). It is unknown whether other organs also have increased
vascular permeability affecting lipid turnover. However, we
cannot rule out that more indirect effects of apoM deficiency
also play a role. Hence, even though only slightly reduced, the
core body temperature was lower in Apom/ mice than in wild-
type mice, which could indirectly stimulate BAT formation. Of
note, the Apom/ mice could be a model of classical heat loss.
This is based on the fact that increased heat loss and BAT mass
in Apom/ mice at 23C are comparable to that in the wild-
type mice exposed to 4C for 6 days, and that Apom/ mice
have a lower core body temperature in thermoneutral environ-
ments. Other models with similar heat loss through the skin also
may protect against diet-induced obesity (Binczek et al., 2007).
Nevertheless, the postprandial clearance of plasma triglycerides
was markedly increased in the Apom/ mice, even when mice
were kept at 30C, which argues against a major effect of the
reducedcorebody temperatureonBATactivity. Increasedadren-
ergic drive and central nervous system-initiated activation can in-
crease BAT activity (Labbe´ et al., 2015). We have, however, not
observed evidence of increased adrenergic drive in apoM-defi-
cient mice, as judged from basic recordings of heart rate or blood
pressure (data not shown). The apoM/S1P axis protects the
blood-brain barrier during inflammatory stimulation (Blaho et al.,
2015), but it is unknownwhether the apoM/S1P axis has direct ef-
fects on central nervous system-induced stimulation of BAT.
Increased amounts of BAT, accelerated turnover of triglycer-
ides, protection from diet-induced obesity, and improved
glucose tolerance suggest a favorable phenotype related to
apoMdeficiency and S1P reduction. Several studies have shown
a similar phenotype in animals with increased BAT activity.
Hence, wild-type mice exposed to chronic cold increase the
BAT activity and improve triglyceride turnover (Bartelt et al.,
2011). Another estimate of BAT activity is RER reduction resem-
bling fat utilization above carbohydrates. Housing animals at
23C and 4C for 6 days did not reveal any solid changes in
RER between Apom/ mice and wild-type mice. However, in
an acute cold environment, Apom/mice experienced a signif-
icant decrease in RER compared to wild-type mice after 12 hr.
This supports that apoM deficiency can modify BAT activity
acutely, even though the body temperature drops. Furthermore,
increased BAT activity reduces hypercholesterolemia and pro-
tects against atherosclerosis (Berbe´e et al., 2015). ApoMdrenergic Stimulation and Cold Exposure on BAT
old exposure (4C) for 6 days.
rom HE-stained sections from 4 Apom/ mice and wild-type mice after cold
4) mice after cold exposure (4C) for 6 days. UCP1 levels were normalized with
(n = 8) mice and Apom/ (n = 8) mice after cold exposure (4C) for 6 days.
ean expression in wild-type (n = 8) mice after cold exposure (4C) for 6 days.
yCs, cytochrome c;
6 hr of acute cold exposure (4C).
utaneously with either saline (n = 4 of each genotype) or CL316243 (n = 5 of each
oc test. #p < 0.05 analyzed by Student’s t test withWelch’s correction. See also
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Figure 4. Apolipoprotein M Affects Postprandial Plasma Triglyceride Metabolism
(A) Area under the plasma triglyceride concentration versus time curve (insert) after an oral gavage of 300 mL olive oil in Apom/ (n = 6) mice or wild-type (n = 6)
mice housed at 23C.
(legend continued on next page)
182 Cell Reports 22, 175–188, January 2, 2018
Table 1. Metabolic Phenotyping of Wild-Type Mice and Apom/ Mice
Light/Dark (12 hr) Genotype Activity (Counts) Core Temperature (C) Food (g) Water (mL) Energy (cal/hr) RER
23C
light wild-type 4,114 ± 225 36.1 ± 0.0 0.8 ± 0.1 0.8 ± 0.1 0.47 ± 0.03 0.89 ± 0.01
Apom/ 4,310 ± 206 35.7 ± 0.1a 0.8 ± 0.1 0.6 ± 0.1 0.43 ± 0.03 0.88 ± 0.01
dark wild-type 10,421 ± 1,335 37.0 ± 0.1 2.9 ± 0.2 2.7 ± 0.1 0.59 ± 0.05 1.03 ± 0.01
Apom/ 12,758 ± 1,523 36.6 ± 0.1a 2.9 ± 0.2 2.5 ± 0.1 0.54 ± 0.04 1.04 ± 0.01
30C
light wild-type 4,105 ± 131 36.1 ± 0.1 0.6 ± 0.1 0.9 ± 0.1 0.25 ± 0.01 0.89 ± 0.00
Apom/ 4,701 ± 216a,b 35.8 ± 0.1a 0.7 ± 0.1 0.8 ± 0.1 0.24 ± 0.02 0.91 ± 0.01b
dark wild-type 10,938 ± 1,266 37.2 ± 0.1 1.7 ± 0.1 2.9 ± 0.3 0.35 ± 0.02 0.98 ± 0.01
Apom/ 12,031 ± 997 37.1 ± 0.1 1.8 ± 0.1 2.8 ± 0.1 0.34 ± 0.03 0.99 ± 0.01
Fasting
light wild-type 3,524 ± 157 34.6 ± 0.3 – 1.4 ± 0.1 0.40 ± 0.06 0.76 ± 0.01
Apom/ 4,073 ± 603 34.6 ± 0.3 – 1.3 ± 0.1 0.26 ± 0.03b 0.75 ± 0.01
dark wild-type 16,723 ± 1,796 35.8 ± 0.1 – 2.1 ± 0.4 0.57 ± 0.07 0.78 ± 0.01
Apom/ 20,935 ± 2,574 35.4 ± 0.3 – 1.9 ± 0.3 0.43 ± 0.06 0.77 ± 0.01
Re-fed
light wild-type 4,875 ± 305 35.9 ± 0.0 1.4 ± 0.1 1.6 ± 0.1 0.56 ± 0.06 1.02 ± 0.01
Apom/ 5,102 ± 232 35.7 ± 0.1a 1.1 ± 0.1b 1.2 ± 0.1b 0.43 ± 0.05 0.97 ± 0.01b
dark wild-type 10,394 ± 495 36.8 ± 0.1 2.6 ± 0.1 3.6 ± 0.2 0.66 ± 0.07 1.04 ± 0.01
Apom/ 11,709 ± 788 36.5 ± 0.1a 2.5 ± 0.2 3.1 ± 0.2 0.51 ± 0.06 1.04 ± 0.01
4C
light (4C) wild-type 5,217 ± 425 35.5 ± 0.1 2.0 ± 0.1 2.8 ± 0.3 0.75 ± 0.04 0.86 ± 0.01
Apom/ 5,263 ± 309 33.7 ± 0.8a 1.7 ± 0.1 2.7 ± 0.2 0.69 ± 0.05 0.84 ± 0.02
dark wild-type 8,218 ± 587 36.7 ± 0.1 2.9 ± 0.2 5.0 ± 0.3 0.62 ± 0.04 1.05 ± 0.01
Apom/ 8,986 ± 420 36.5 ± 0.1 2.9 ± 0.2 4.7 ± 0.1 0.58 ± 0.04 1.09 ± 0.01b
light wild-type 4,799 ± 490 36.5 ± 0.1 1.6 ± 0.2 4.1 ± 1.1 0.51 ± 0.07 0.94 ± 0.02
Apom/ 5,821 ± 226b 36.2 ± 0.1 1.3 ± 0.1 4.0 ± 0.2 0.69 ± 0.07b 0.95 ± 0.02
dark (4C) wild-type 8,771 ± 865 36.1 ± 0.1 2.8 ± 0.3 2.7 ± 0.3 1.01 ± 0.10 0.86 ± 0.04
Apom/ 7,688 ± 637 35.6 ± 0.2a 3.5 ± 0.3b 2.2 ± 0.2 1.06 ± 0.11 0.88 ± 0.03
Food, water, O2, CO2, activity, and temperature were recorded. The animals were housed at 23
C, fasted for 24 hr, refed, and housed at 30C, 23C,
and 4C. See also Figures S3 and S4 and Table S1.
aValues are means ± SEMs, n = 8 in each group, p < 0.05 using Student’s t test.
bValues are means ± SEMs, n = 8 in each group, p < 0.05 using ANCOVA statistical testing.overexpression in mice can increase cholesterol efflux from
macrophages, protect against oxidation of LDL, and reduce
atherosclerosis (Christoffersen et al., 2008). However,
Apom/ldlr/ mice had surprisingly reduced levels of choles-
terol and atherosclerosis (Christoffersen et al., 2010). Whether
this unexplained phenotype could be related to the herein-
described increased BAT activity in Apom/ mice is unknown,
but it has been shown that BAT activation protects against
atherosclerotic development (Berbe´e et al., 2015).(B) Plasma lipase activity 10 min after intravenous injection of heparin in Apom
(C) Plasma triglyceride concentrations after intravenous injection of Triton WR-1
(D) Tissue uptake of 3H-triolein 4 hr after oral gavage with 300 mL 3H-triolein-con
(E and F) Tissue uptake of 3H-cholesterylhexadecylether (E) and 14C-triolein (
lipoproteins in Apom/ (n = 9) mice and wild-type (n = 8) mice.
(G and H) Blood glucose (G) and area under the blood glucose concentration (H) v
mice or wild-type (n = 7–8) mice fed chow (open symbols) or high-fat diet (filled
Error bars represent SEM. # p < 0.05 analyzed by Student’s t test with Welch’s cThe increased turnover of postprandial triglycerides in
Apom/mice was associated with the increased uptake of fatty
acids and artificial double-labeled whole lipoprotein particles
in BAT. Also, BAT displayed increased vascular permeability
in Apom/ mice. The latter finding likely reflects diminished
S1P1 receptor stimulation (Christensen et al., 2016). The
increased permeability may provide easier access for lipopro-
teins to the BAT adipocytes and even endothelial-bound
LPL, which could contribute to accelerated tissue uptake of/ (n = 26) mice or wild-type (n = 22) mice.
339 in Apom/ (n = 5) mice or wild-type (n = 5) mice.
taining olive oil in Apom/ (n = 6) mice and wild-type (n = 6) mice.
F) 10 minutes after intravenous injection of double-labeled triglyceride-rich
ersus time curve after an intraperitoneal injection of glucose in Apom/ (n = 8)
symbols) for 10 weeks (H).
orrection. See also Figure S3 and Table S1.
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triglycerides (Williams and Fisher, 2011). However, altered lipid
metabolism in other tissues also may play a role. Thus, the
increased clearance of postprandial triglycerides was seen
even at 30C, when BAT uptake of glucose was diminished.
Indeed, apoM deficiency altered the gene expression profile of
WAT and increased postheparin LPL concentrations in plasma.
Several apolipoproteins in very low-density lipoproteins (VLDLs)
and chylomicrons, such as apoCI, apoCII, apoCIII, and apoAV,
regulate and interact with LPL (Clavey et al., 1995; Gangabadage
et al., 2008; Goldberg et al., 1990; Shen et al., 2002). ApoM also
is present on chylomicrons and VLDLs (Xu and Dahlba¨ck, 1999),
even though only 4%–5%of plasma apoM is bound to other lipo-
proteins than HDLs (Christoffersen et al., 2006). We do not sus-
pect, however, that a direct interaction with LPL plays a major
role, because the plasma concentration of apoM in non-HDLs
is rather low (<50 mmol/L) and because BAT uptake of artificial
double-labeled whole particles was increased in the Apom/
mice. Notably, plasma ANGPLT4, which regulates the activity
of LPL (Dijk et al., 2015; Ko¨ster et al., 2005), was similar in
Apom/ mice and wild-type mice (data not shown).
Interestingly, previous results support that the S1P system
indeed affects triglyceride metabolism. Thus, in mice, sphingo-
sine kinase 2 inhibition reduced both plasma S1P and triglycer-
ides (Poti et al., 2012; Potı` et al., 2015), whereas S1P-lyase defi-
ciency increased plasma S1P and triglycerides (Bektas et al.,
2010). Moreover, FTY720 accelerates lipolysis in vitro (Moon
et al., 2012), implying direct effects of S1P on adipocyte biology.
When used for its S1P1-agonizing effects in treating patients with
multiple sclerosis, dyslipidemia is awell-accepted adverse effect
of FTY720 (Kim et al., 2015). In the present study, both FTY720
and the S1P1 antagonistW146 increasedBATmass and reduced
postprandial triglycerides inwild-typemice. Furthermore, the pri-
mary source of S1P, ceramide, also has been investigated
recently for its roles in browning of adipocytes and metabolism
(Chaurasia et al., 2016). The study found that the inhibition of
ceramide induces browning of subcutaneous WAT, accelerates
energy expenditure, and protects against diet-induced obesity.
However, the authors did not find any significant effect of cer-
amide on BAT. These data and the present study support that
sphingolipids can influence the metabolic activity and insulin
sensitivity in adipose tissue. They also suggest that an increased
amount of and activity in BAT are likely the result of a specific
phenotype induced by S1P/apoM and its receptors. Hence, theFigure 5. S1P1 Antagonism Increases BAT Formation and Clearance o
(A) BAT mass in wild-type (n = 6) mice and Apom/ (n = 7) mice treated with sa
(B) IsBAT mass in wild-type mice and Apom/ mice treated with S1P1 agonist S
(C) UCP1mRNA expression in 3T3-L1 cells differentiated into beige adipocytes in
S1P, SEW2871, W146, or FTY720.
(D) Endothelial permeability was measured as uptake of Evans Blue per gram BA
(E) BAT volume measured by PET-CT scanning in mice (n = 4–5) receiving eith
representative Apom/ mice housed at 30C. White and red arrows indicate FD
(F) Plasma triglyceride concentrations after an oral gavage of 300 mL olive oil in w
(G) Area under plasma triglyceride concentration versus time curve (4 hr) after oral
with saline or FTY720 before fat challenge.
(H) Tissue uptake of 3H-triolein 4 hr after oral gavage with 300 mL triolein-containing
or saline.
Error bars represent SEM. *p < 0.05 using one-way ANOVA with Bonferroni post
appropriate. See also Figures S5 and S6.present data should spark investigations to unravel a putative
beneficial role of inhibiting the S1P1 in, e.g., obesity and
increased postprandial lipedema. Indeed, increased activity of
BAT in humans has been associated with improved metabolic
health from increased lipid metabolism, glucose uptake, and
weight loss (Bartelt and Heeren, 2014; Cawthorne et al., 1984;
Peirce andVidal-Puig, 2013; Vallerand et al., 1986), and obese in-
dividuals also have reduced levels of BAT (van Marken Lichten-
belt et al., 2009). Inhibition of the apoM/S1P axis may provide a
tool to address the extent to which stimulation of BAT is an effec-
tive means for improving metabolism in adult humans.
EXPERIMENTAL PROCEDURES
Animals
Mice were housed at the Panum Institute (University of Copenhagen) in a
temperature-controlled facility with a 12-hr dark/light cycle and fed standard
chow or a high-fat-containing diet. Only female mice were used throughout
the study. All of the procedures were approved by the Animal Experiments
Inspectorate, Ministry of Justice, Denmark.
Isolation of Tissue
Animals were anesthetized before blood sampling from the orbital vein;
animals were perfused with saline before dissection of the liver, epiWAT, sub-
WAT, quadriceps muscle, IsBAT, and subscapular BAT.
Plasma Analysis
Plasma triglycerides were measured with enzymatic kits (GPO Trinder,
Sigma-Aldrich). Lipoprotein lipase activity was evaluated with the Lipase Ac-
tivity Assay (cat. no. 700640, Cayman Chemical). To explore the secretion
rate of triglyceride from the liver, Triton WR-1339 (0.5 g/kg body weight
[BW]) was injected intravenously (i.v.) into mice after fasting overnight (n = 5).
RNA and Protein Extraction
RNA was isolated with Trizol (Invitrogen). First-strand cDNA synthesis was
performed using High Capacity cDNA reverse Transcription Kit (Applied Bio-
systems) and quantitative real-time PCR analysis was done with a TaqMan
ABI PRISM 7900HT Sequence Detection System (Applied Biosystems). UCP1
protein levelswere analyzedbyWesternblottingusingananti-mouseUCP1anti-
body (Abcam 23841). Glyceraldehyde-3-phosphate dehydrogenase (GAPDH)
was detected with an antibody (SC257787) from Santa Cruz Biotechnology.
Cardiolipin Measurement
Lipids were extracted with chloroform/methanol from BAT as described (Bar-
tels et al., 2002) fromApom/ (n = 8)mice andwild-type (n = 7–8)mice housed
at 23C or 4C. The extracts were analyzed by quantitative thin-layer
chromatography.f Postprandial Plasma Triglycerides
line or FTY720.
EW2871 (n = 6–7), S1P1 antagonist W146 (n = 6–8), or saline (n = 10–14).
the present of either phosphate-buffered saline (PBS), HDL+apoM, HDL-apoM,
T.
er saline or the b3-agonist CL316243 before FDG. PET-CT images are from
G uptake in BAT and heart, respectively.
ild-type (n = 6) mice and Apom/ (n = 7) mice housed for 7 days at 30C.
gavage of 300 mL olive oil inApom/ (n = 7) mice or control (n = 7) mice treated
olive oil inApom/ (n = 6) mice andwild-type (n = 6)mice treated with FTY720
hoc test. #p < 0.05 analyzed by Student’s t test with Welch’s correction when
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Histology
BAT and WAT isolated from Apom/ (n = 4) and wild-type (n = 4) mice sacri-
ficed at 23C or 4C were embedded in paraffin and stained with Mayer’s he-
matoxylin and eosin (HE; Dako). Histological analyses were conducted with a
Leitz Diaplan (Leica) microscope. Pictures were acquired with a Leica DFC290
digital camera and analyzed with the Leica IM50 software.
Thermographic Measurement
Tail or body surface temperature in animals was measured with a FLIR E6
thermographic camera at a distance of 15 cm. Recordings were repeated
at least 4 times at each time point and analyzed with FLIR Tool+ and FLIR
ResearchIR.
Clearance of Plasma Triglycerides
After overnight fasting, mice received olive oil (300 mL) or olive oil supple-
mented with 3H-triolein by oral gavage. After 240 min, the animals were sacri-
ficed and perfusedwith 0.9%NaCl. Tissue biopsies were dissolved in Solvable
(PerkinElmer). 3H was counted in a Wallac 1409 Liquid Scintillation Counter
(PerkinElmer). To measure whole triglyceride particle uptake in tissues, mice
were injected intravenously with triglyceride-rich lipoproteins labeled with
14C-triolein and 3H-cholesterylhexadecylether as described (Bartelt et al.,
2011).
Metabolic Phenotyping
Apom/ (n = 8) mice and wild-type (n = 8) mice were housed individually and
monitored with an indirect calorimetry system (PhenoMaster, TSE Systems,
Germany). The animals were housed at 23C, fasted for 24 hr, refed, and
housed at 30C, at 23C, and finally at 4C. Animals were acclimatized for
3 days at each temperature before recordings were made. To estimate the ef-
fect of acute cold exposure, Apom/ (n = 8) mice and wild-type (n = 8) mice
were housed at 30C for 3 days and moved directly into environmental cham-
bers (TSE Systems) at 4C for 16 hr. To test the effect of a high-fat diet,
Apom/ (n = 8) mice and wild-type (n = 8) mice were housed at 23C for
3 days, fasted for 12 hr, and refed a high-fat diet.
Vascular Permeability
Mice received an intravenous injection of Evans Blue. Evans Blue uptake in
BAT was measured after 30 min as described (Christoffersen et al., 2011).
PET-CT
An intravenous injection of 10 MBq FDG was administered to mice 1 hr before
PET-CT scanning (Inveon multimodality PET-CT scanner, Siemens).
Drug Treatment
Fingolimod (Sigma-Aldrich) or saline was administered by oral gavage
(0.5 mg/kg body weight mice) (Blaho et al., 2015). SEW2871 (10 mg/kg;
S3944, Sigma-Aldrich, Brøndby, Denmark) (10 mg/kg), W146 (10 mg/kg;
W1020, Sigma-Aldrich), and b3 receptor agonist CL316243 (1 mg/kg) or saline
were injected subcutaneously (Bartelt et al., 2013).
MRI
Animals were acclimatized at 23C for 7 days before fat and lean body mass
was measured with MRI with EchoMRI 4in1-700 (Houston, TX, USA).
Statistical Analysis
Differences between groups were analyzed with one-way ANOVA, post hoc
test, and Student t test using Welch’s correction for unequal variances when-
ever appropriate. For statistical evaluation of the data obtained in metabolic
cages, SPSS was used following the appropriate guidelines (Speakman
et al., 2013).
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